证券日报网讯 2月4日，贝达药业在互动平台回答投资者提问时表示，公司经营正常，不存在法规要求 发布业绩预告的相关情形，并已预约2026年4月23日披露2025年年度报告。 （文章来源：证券日报） ...

证券日报网讯 2月4日，贝达药业在互动平台回答投资者提问时表示，公司已按工作业务的相关进展预 约2026年4月23日为2025年年度报告披露日。目前公司经营正常，2025年业绩相关信息请以公司公开披 露为准。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 2月4日，贝达药业在互动平台回答投资者提问时表示，公司年度报告披露时间根据深圳 证券交易所的预约披露统筹安排，并结合公司实际情况、审计工作进展及内部审议程序等因素确定，公 司将在预约期限内完成年报的编制与披露工作。 ...

Group 1 - The core viewpoint of the article highlights that Beida Pharmaceutical (300558) is experiencing steady sales growth for its eight listed drugs and is gradually expanding into overseas markets [1] - The company is concentrating resources on the development of key projects and is increasing its investment in new targets and technologies to expedite the launch of new products [1]

每经AI快讯，有投资者在投资者互动平台提问：据公开信息，公司多次提到布局ADC产品项目。请问 董秘，这是自研产品还是从生态圈战略合作伙伴引进？ 贝达药业（300558.SZ）2月4日在投资者互动平台表示，公司尚未有自研ADC产品项目立项，将通过生 态圈联动合作伙伴积极关注ADC产品项目，后续如有相关重大节点进展，公司会及时公开披露。 （文章来源：每日经济新闻） ...

每经AI快讯，贝达药业（300558.SZ）2月4日在投资者互动平台表示，公司经营正常，不存在法规要求 发布业绩预告的相关情形，并已预约2026年4月23日披露2025年年度报告，届时请您关注公司发布的相 关公告。 （文章来源：每日经济新闻） ...

（文章来源：每日经济新闻） 每经AI快讯，贝达药业（300558.SZ）2月4日在投资者互动平台表示，您好！创新药的开发是一项长期 的、艰巨的探索工作，MCLA-129作为EGFR/c-MET双特异性抗体，已在晚期非小细胞肺癌领域积累了 颇具价值的临床数据。近日，MCLA-129与恩沙替尼联合用药I/II期临床研究已完成首例受试者入组，期 待在与研究机构和专家们的共同努力下，进一步验证该联合治疗方案的临床潜力，为MET扩增或过表 达晚期实体瘤患提供更多治疗选择。 ...

格隆汇2月4日丨贝达药业(300558.SZ)在投资者互动平台表示，公司自研尚未有ADC产品项目立项，将 通过生态圈联动合作伙伴积极关注ADC产品项目，后续如有相关重大节点进展，公司会及时公开披 露。 ...

Core Insights - Tosun Pharmaceutical, a biopharmaceutical innovation company founded by Professor Liu Yongjun, has completed a $40 million angel round financing [1] - The financing round was led by Qiji Investment and Jiadao Capital, with participation from several notable institutions including Hongning Hengtai, Betta Pharmaceuticals, Tigermed, and others [1] - The raised funds will primarily be used to advance the research and development of third-generation antibody-drug conjugates (ADCs), focusing on multi-target layouts, innovative design of differentiated payloads, and the development of oncology pipelines [1]

Core Insights - Sequoia China, known for investing in innovative drugs and cutting-edge biotech, has made a surprising acquisition of the classic antibiotic Moxifloxacin (Avelox) from Bayer, establishing a new biopharmaceutical platform, Hangzhou Sanzhe Biopharmaceutical Co., Ltd. [1][2] - The acquisition is seen as a strategic move to leverage Moxifloxacin's existing market presence and cash flow while also aiming to introduce innovative products into the pipeline [5][8] Group 1: Acquisition Details - The acquisition involves Moxifloxacin, which has treated over 240 million patients globally, and includes key assets such as drug registration certificates and intellectual property [1][3] - Moxifloxacin was once a blockbuster drug for Bayer, generating nearly $1.2 billion in global sales in 2012, but has seen a decline in sales due to patent expiration and increased competition from generics [3][4] - In China, Bayer's market share for Moxifloxacin was approximately 34.75% in 2022, with local competitors capturing over 25% of the market [3] Group 2: Strategic Implications - Sequoia's acquisition reflects a shift from traditional VC investment strategies to a more private equity (PE) approach, focusing on optimizing and integrating mature businesses for stable cash flow [5][6] - The transaction is estimated to be between €160 million and €260 million, supported by financing from Shanghai Pudong Development Bank, indicating a leveraged buyout strategy [6][7] - The new platform, Sanzhe Biopharmaceutical, aims to operate Moxifloxacin as a "cash cow" while also serving as a foundation for introducing innovative products [7][8] Group 3: Leadership and Execution - Jin Xiaodong, a seasoned executive with extensive experience in multinational pharmaceutical companies, has been appointed to lead Sanzhe Biopharmaceutical, aligning with the company's dual strategy of managing mature products and seeking innovative assets [10][12] - Jin's background in commercializing mature products and his experience in strategic partnerships are seen as critical for the success of the new platform [11][12] Group 4: Challenges Ahead - Reviving Moxifloxacin in a competitive market, particularly under China's centralized procurement policies, presents a significant challenge for Sanzhe Biopharmaceutical [15] - The search for high-quality late-stage innovative assets is crucial, as the success of the strategy hinges on acquiring promising candidates in a competitive landscape [15][16] - Building an effective team and integrating the acquired global business with the new company's strategic goals will be essential for long-term success [16]